biomedical device News
-
Avery Biomedical Letter to Medscape Regarding Diaphragm Pacing
Please find below a letter that our attorney sent to the editors of Medscape (parent company WebMD) who have published false information about our product. Medscape Letter Regarding Avery System Avery Biomedical Devices has an outstanding track record spanning over 45 years including an outstanding safety record, long term viability with some patients pacing for more than 35 years, and ...
-
USMI to Announce Successful Results of Phase I Clinical Trial Using Cold Atmospheric Plasma for the Treatment of Solid Tumors at the Baird 2021 Global Healthcare Conference
US Medical Innovations, LLC (USMI), a U.S. FDA-registered life-science and biomedical device company and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) announced today that Jerome Canady MD, CEO will be presenting at the Baird Global Healthcare Conference on Tuesday, September 14th from 10:15 to 10:45 AM ET. Dr. Canady will present results ...
-
Avery Biomedical Devices’ Nextgen Diaphragm Pacing Transmitter, Spirit, Earns FDA Approval – Now Available
Avery Biomedical Devices (Commack, NY), the global leader in high reliability diaphragm pacemakers, announced that its new diaphragm pacemaker transmitter, Spirit, has earned FDA approval and is now being offered to patients using its pacing system. This NextGen transmitter features a light-weight compact design with easy-to-use touch controls and offers precision-enhancing digital ...
-
Fibralign Announces CE Mark Approval for BioBridge
Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced that it has received CE mark for its first product, the BioBridge Collagen Matrix. BioBridge is classified as a Class III device with an indication for use to support lymphatic tissue repair and can be used after or in conjunction with surgical procedures addressing lymphedema. CE mark is a ...
-
ABK Biomedical Inc. Raises $30M USD in Series B Financing
ABK Biomedical, Inc., a medical device company dedicated to the research, development and commercialization of innovative embolic therapies, announced a $30 million USD Series B financing. The round is co-led by F-Prime Capital and Varian Medical Systems. ABK Biomedical will use the funding for continued focused product development of its Eye90 microspheres™, which are designed for ...
-
Fibralign Announces Start of European Lymphedema Prevention Clinical Study
Fibralign Corp., a Stanford spin-out and developer of therapeutic biomedical devices, today announced enrollment of the first patient in a multi-site, randomized clinical trial in Europe evaluating its BioBridge® Collagen Matrix as a novel preventative treatment for secondary lymphedema. The study plans to enroll 40 patients that have been diagnosed with advanced stage breast cancer and ...
-
Fibralign Announces Strategic Partnership with Terumo
Fibralign Corp., a Stanford spin-out developer of therapeutic biomedical devices, has announced today that it has executed a long term distributor agreement with Terumo Corporation to market and distribute the BioBridge® Collagen Matrix in Japan for treating and preventing secondary lymphedema. BioBridge is a sterile implantable biocompatible and biodegradable surgical mesh made of highly ...
-
UChicago Medicine Enrolling Patients in Lymphbridge Clinical Study for Surgical Treatment of Breast Cancer-Related Lymphedema
The University of Chicago Medicine has announced today that it is now enrolling patients into LymphBridge, a randomized clinical study to evaluate a novel investigational surgical device for the treatment of breast cancer-related lymphedema. This study is sponsored by Fibralign Corporation with funding provided by the National Cancer Institute (NCI) and being led by world-renowned microsurgeon ...
-
JCRI Discovers the Mechanism using Canady Helios Cold Plasma to Induce Cell Death in Breast Cancer
The Jerome Canady Research Institute for Advanced Biological and Technological Sciences (JCRI-ABTS), in collaboration with US Medical Innovations, LLC (USMI), announced today that they have discovered the mechanism using Canady Helios™ Cold Plasma (CHCP) to induce cell death in breast cancer. Recently accepted for publication in the International Journal of Molecular Sciences, the article ...
-
USMI Developing the First Surgical Robot for Cancer Surgery
US Medical Innovations, LLC (USMI) announced today that it is developing the first robotic delivery system used for cancer surgery. The new Canady Surgical System (CSS) is a space-efficient, cost-effective, stand-alone solution for Robotic Assisted Surgery during open, laparoscopic/mini-invasive, endoscopic, thoracoscopic and trans-oral surgical procedures. Features of the new Canady Surgical ...
-
Diaphragm Pacemaker for Teen Featured on WSB-TV Atlanta
Fourteen year-old Sedarius was recently featured on WSB-TV Atlanta as the first pediatric patient to receive surgery to implant a diaphragm pacemaker in the state of Georgia. Sedarius was diagnosed with CCHS when he was eight years old, and required a tracheotomy and ventilator to breathe while he slept. The Avery Breathing Pacemaker will allow him to breathe without the need for a trach or ...
-
CCHS Foundation Announces Fifth International CCHS Day with Celebrity Champions Henry Winkler and Jonah Hill
The CCHS Foundation proudly announces the 5th Annual International CCHS Day on November 9, 2019. The CCHS Foundation is the fundraising arm of the CCHS Network, a support and advocacy organization for families living with Congenital Central Hypoventilation Syndrome (CCHS). CCHS is a multisystem disorder of the central nervous system where, most dramatically, the automatic control of breathing ...
-
USMI and JCRI Research Teams Develop Treatment System for COVID and other Respiratory Infections and Diseases
US Medical Innovations, LLC (USMI) and the Jerome Canady Research Institute for Advanced and Biological Technological Sciences (JCRI-ABTS) announced today that the United States Patent and Trademark Office has issued a Notice of Allowance in connection with JCRI-ABTS’s US National Stage Application (Serial No. 17/284,762) entitled “SYSTEM FOR TREATMENT OF RESPIRATORY INFECTIONS AND ...
-
CONMED Announces Definitive Agreement to Acquire Biorez, Inc.
LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced a definitive agreement to acquire privately held Biorez, Inc. (Biorez), on a cash-free, debt-free basis, for cash consideration of $85 million at closing, subject to adjustment, and up to an additional $165 million in growth-based earnout payments over a four-year period. The transaction is expected to be ...
By Biorez Inc.
-
JCRI-ABTS and USMI Successfully Complete Phase 1 Multi-Center Clinical Trial Using Canady Helios™ Cold Plasma for the Treatment of Cancer
The Jerome Canady Research Institute for Advanced Biological and Technological Sciences, LLC (JCRI-ABTS) and US Medical Innovations, LLC (USMI) announced today that they have successfully completed Phase 1 in their Clinical Trial using Canady Helios™ Cold Plasma (CHCP) for the treatment of recurrent and stage 4 solid tumors (IDE #G190195). The medical centers involved in the study were Rush ...
-
Mitigating Aspergillus Infection Risks in Hospitals and Buildings across Puerto Rico
A potentially life-threatening condition known as aspergillosis is caused by a fungal pathogen named Aspergillus. It is a common type mold that can often be found outdoors and in indoor environments that have suffered water damage or elevated humidity levels. Fortunately, most healthy people breathe Aspergillus spores without infection concerns. However, some species are known to be a serious ...
-
Aspergillus Infection Risks in Hospitals, Homes and Buildings
Aspergillosis is a potentially life-threatening condition caused by a fungal pathogen known as Aspergillus. It is a common type of mold found outdoors and in indoor environments. It can be found at excessive concentrations indoors when buildings suffer water damage or elevated humidity levels. Fortunately, most healthy people breathe Aspergillus spores without infection concerns. However, some ...
-
Alfa Chemistry Now Becomes A High-Quality 2D Material Supplier
Making use of expanded facilities and advanced material characterization techniques, Alfa Chemistry has added specialization in designing and synthesizing a wide range of 2D materials for researchers for universities, research institutions, and companies worldwide. In materials science, two-dimensional (2D) materials, also referred to as single-layer materials, are substances with a thickness of ...
-
BICO acquires Allegro 3D, adding new light-based 3D bioprinting technology – complementing the existing offering of application tailored products
Adding Allegro 3D to the portfolio enables BICO Bioprinting to strengthen its position as the global leader in providing 3D bioprinters. BICO has a robust portfolio of bioprinters, utilizing extrusion based, 2PP and DLP technologies. BICO has acquired all the shares in San Diego-based Allegro 3D Inc. (“Allegro 3D”) for an up-front enterprise value of USD 6 million. Additionally, ...
-
Reprise Biomedical Completes Spin-off from Miromatrix Medical
Reprise Biomedical, Inc., a Minnesota-based startup focused on commercializing biological medical devices manufactured using a proprietary perfusion decellularization technology, has successfully completed a $12.5 million private placement and commenced operations as a spin-off from Miromatrix Medical Inc. Through the spin-off, Miromatrix transferred to Reprise two existing FDA 510(k) cleared, ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you